Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Inflammation Research
Published in: Inflammation Research 3/2018

01-03-2018 | Review

Decursin and decursinol angelate: molecular mechanism and therapeutic potential in inflammatory diseases

Authors: Adeeb Shehzad, Sajida Parveen, Munibah Qureshi, Fazli Subhan, Young Sup Lee

Published in: Inflammation Research | Issue 3/2018

Login to get access

Abstract

Epidemiological studies have shown that inflammation plays a critical role in the development and progression of various chronic diseases, including cancers, neurological diseases, hepatic fibrosis, diabetic retinopathy, and vascular diseases. Decursin and decursinol angelate (DA) are pyranocoumarin compounds obtained from the roots of Angelica gigas. Several studies have described the anti-inflammatory effects of decursin and DA. Decursin and DA have shown potential anti-inflammatory activity by modulating growth factors such as vascular endothelial growth factor, transcription factors such as signal transducer and activator of transcription 3 and nuclear factor kappa-light-chain-enhancer of activated B cells, cellular enzymes including matrix metalloproteinases cyclooxygenase, and protein kinases such as extracellular receptor kinase, phosphatidylinositol-3-kinase, and protein kinase C. These compounds have the ability to induce apoptosis by activating pro-apoptotic proteins and the caspase cascade, and reduced the expression of anti-apoptotic proteins such as B-cell lymphoma 2 and B-cell lymphoma-extra-large. Interaction with multiple molecular targets and cytotoxic effects, these two compounds are favorable candidates for treating various chronic inflammatory diseases such as cancers (prostate, breast, leukemia, cervical, and myeloma), rheumatoid arthritis, diabetic retinopathy, hepatic fibrosis, osteoclastogenesis, allergy, and Alzheimer’s disease. We have summarized the preliminary studies regarding the biological effects of decursin and DA. In this review, we will also highlight the functions of coumarin compounds that can be translated to a clinical practice for the treatment and prevention of various inflammatory ailments.
Literature
1.
Atanasov AG, Waltenberger B, Pferschy-Wenzig EM, et al. Discovery and resupply of pharmacologically active plant-derived natural products: a review. Biotechnol Adv. 2015;33:1582–614.CrossRefPubMedPubMedCentral
2.
Choi KO, Lee I, Paik SY, Kim DE, Lim JD, Kang WS, Ko S. Ultrafine Angelica gigas powder normalizes ovarian hormone levels and has antiosteoporosis properties in ovariectomized rats: particle size effect. J Med Food. 2012;15:863–72.CrossRefPubMedPubMedCentral
3.
Yim D, Singh RP, Agarwal C, Lee S, Chi H, Agarwal R. A novel anticancer agent, decursin, induces G1 arrest and apoptosis in human prostate carcinoma cells. Cancer Res. 2005;65:1035–44.CrossRefPubMed
4.
Kim WJ, Lee MY, Kim JH, Sukb K, Lee WH. Decursinol angelate blocks transmigration and inflammatory activation of cancer cells through inhibition of PI3K, ERK and NF-kB activation. Cancer Lett. 2010;296:35–42.CrossRefPubMed
5.
Jung SY, Choi JH, Kwon SM, Masuda H, Asahara T, Lee YM. Decursin inhibits vasculogenesis in early tumor progression by suppression of endothelial progenitor cell differentiation and function. J Cell Biochem. 2012;113:1478–87.PubMed
6.
Jiang C, Guo J, Wang Z, Xiao B, Lee HJ, Lee EO, Lu J. Decursin and decursinol angelate inhibit estrogen-stimulated and estrogen-independent growth and survival of breast cancer cells. Breast Cancer Res. 2007;9:1.CrossRef
7.
Kim JH, Kim JH, Lee YM, Ahn EM, Kim KW, Yu YS. Decursin Inhibits VEGF-mediated inner blood—retinal barrier breakdown by suppression of VEGFR-2 activation. J Cereb Blood Flow Metab. 2009;29:1559–67.CrossRefPubMed
8.
Son SH, Kim MJ, Chung WY, Son JA, Kim YS, Kim YC, Park KK. Decursin and decursinol inhibit VEGF-induced angiogenesis by blocking the activation of extracellular signal-regulated kinase and c-Jun N-terminal kinase. Cancer Lett. 2009;280:86–92.CrossRefPubMed
9.
Lee B, Wu Z, Sung SH, Lee T, Song KS, Lee MY, Liu KH. Potential of decursin to inhibit the human cytochrome P450 2J2 isoform. Food Chem Toxicol. 2014;70:94–9.CrossRefPubMed
10.
Yim NH, Lee JH, Cho WK, Yang MC, Kwak DH, Ma JY. Decursin and decursinol angelate from Angelica gigas Nakai induce apoptosis via induction of TRAIL expression on cervical cancer cells. Eur J Integr Med. 2011;3:299–307.CrossRef
11.
Choi YJ, Kim DH, Kim SJ, Kim J, Jeong SI, Chung CH, Kim SY. Decursin attenuates hepatic fibrogenesis through interrupting TGF-beta-mediated NAD (P) H oxidase activation and Smad signaling in vivo and in vitro. Life Sci. 2014;108:94–103.CrossRefPubMed
12.
Zitvogel L, Pietrocola F, Kroemer G. Nutrition, inflammation and cancer. Nat Immunol. 2017;18:843–50.CrossRefPubMed
13.
Younis T, Haché KD, Rayson D, Dewar R, Gray S, Barnes PJ. Survivin and COX-2 expression in male breast carcinoma. Breast. 2009;18:228–32.CrossRefPubMed
14.
Arunasree KM, Roy KR, Anilkumar K, Aparna A, Reddy GV, Reddanna P. Imatinib-resistant K562 cells are more sensitive to celecoxib,A selective COX-2 inhibitor. Role of COX-2 and MDR-1. Leuk Res. 2008;32:855–64.CrossRefPubMed
15.
Ahn Q, Jeong SJ, Lee HJ, Kwon HY, Han I, Kim HS, Zhu S. Inhibition of cyclooxygenase-2-dependent survivin mediates decursin-induced apoptosis in human KBM-5 myeloid leukemia cells. Cancer Lett. 2010;298:212–21.CrossRefPubMedPubMedCentral
16.
Shin S, Joo SS, Park D, Jeon JH, Kim TK, Kim JS, Park SK, Hwang BY, Kim YB. Ethanol extract of Angelica gigas inhibits croton oil-induced inflammation by suppressing the cyclooxygenase—prostaglandin pathway. J Vet Sci. 2010;11:43–50.CrossRefPubMedPubMedCentral
17.
Yoo HH, Lee MW, Kim YC, Yun CH, Kim DH. Mechanism-based inactivation of cytochrome P450 2A6 by decursinol angelate isolated from Angelica gigas. Drug Metab Dispos. 2007;35:1759–65.CrossRefPubMed
18.
Satarug S, Ujjin P, Vanavanitkun Y, Nishijo M, Baker JR, Moore MR. Effects of cigarette smoking and exposure to cadmium and lead on phenotypic variability of hepatic CYP2A6 and renal function biomarkers in men. Toxicology. 2004; 204:161–73.CrossRefPubMed
19.
Enayetallah AE, French RA, Thibodeau MS, Grant DF. Distribution of soluble epoxide hydrolase and of cytochrome P450 2C8, 2C9, and 2J2 in human tissues. J Histochem Cytochem.2004; 52:447–54.CrossRefPubMed
20.
Wu S, Moomaw CR, Tomer KB, Falck JR, Zeldin DC. Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem. 1996;271:3460–68.CrossRefPubMed
21.
Chen C, Wei X, Rao X, Wu J, Yang S, Chen F, Wang DW. Cytochrome P450 2J2 is highly expressed in hematologic malignant diseases and promotes tumor cell growth. J Pharmacol Exp Ther. 2011;336:344–55.CrossRefPubMedPubMedCentral
22.
Jiang JG, Chen CL, Card JW, Yang S, Chen JX, Fu XN, Ning YG, Xiao X, Zeldin DC, Wang DW. Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors. Cancer Res. 2005;65:4707–15.CrossRefPubMed
23.
Lamalice L, Houle F, Jourdan G, Huot J. Phosphorylation of tyrosine 1214 on VEGFR2 is required for VEGF-induced activation of Cdc42 upstream of SAPK2/p38. Oncogene. 2004;23:434–45.CrossRefPubMed
24.
Jung MH, Lee SH, Ahn EM, Lee YM. Decursin and decursinol angelate inhibit VEGF-induced angiogenesis via suppression of the VEGFR-2-signaling pathway. Carcinogenesis. 2009;30:655–61.CrossRefPubMed
25.
Yao JS, Chen Y, Zhai W, Xu K, Young WL, Yang GY. Minocycline exerts multiple inhibitory effects on vascular endothelial growth factor-induced smooth muscle cell migration the role of ERK1/2, PI3K, and matrix metalloproteinases. Circ Res. 2004;95:364–71.CrossRefPubMed
26.
Chen CH, Chang LT, Tung WC, et al. “Levels and values of circulating endothelial progenitor cells, soluble angiogenic factors, and mononuclear cell apoptosis in liver cirrhosis patients. J Biomed Sci. 2012;19:66–77.CrossRefPubMedPubMedCentral
27.
Bank S, Andersen PS, Burisch J, et al. polymorphisms in the toll-like receptor and the il-23/il-17 pathways were associated with susceptibility to inflammatory bowel disease in a danish cohort. Plos One. 2015;10:e0145302.CrossRefPubMedPubMedCentral
28.
Pant S, Deshmukh A, Gurumurthy GS, Pothineni NV, Watts TE, Romeo F, Mehta JL. Inflammation and atherosclerosis–revisited. J Cardiovasc Pharmacol Ther. 2014;19:170–8.CrossRefPubMed
29.
30.
Shehzad A, Islam SU, Ahn EM, Lee YM, Lee YS. Decursinol angelate inhibits PGE2-induced survival of the human leukemia HL-60 cell line via regulation of the EP2 receptor and NFκB pathway. Cancer Biol Ther. 2016;17:985–93.CrossRefPubMedPubMedCentral
31.
Walter S, Letiembre M, Liu Y, Heine H, Penke B, Hao W, Bode B, Manietta N, Walter J, Schulz-Schuffer W, Fassbender K. Role of the toll-like receptor 4 in neuroinflammation in Alzheimer’s disease. Cell Physiol Biochem. 2007; 20:947–56.
32.
33.
Jiang C, Lee HJ, Li GX, Guo J, Malewicz B, Zhao Y, Kim SH. Potent antiandrogen and androgen receptor activities of an Angelica gigas-containing herbal formulation: identification of decursin as a novel and active compound with implications for prevention and treatment of prostate cancer. Cancer Res. 2006;66:453–63.CrossRefPubMed
34.
Kim JH, Jeong JH, Jeon ST, Kim H, Ock J, Suk K, Lee WH. Decursin inhibits induction of inflammatory mediators by blocking nuclear factor-κB activation in macrophages. Mol pharmacol. 2006;69:1783–90.CrossRefPubMed
35.
36.
Kim JM, Noh EM, Kim MS, Hwang JK, Hwang HY, Ryu DG, Kim HJ, Yu HN, You YO, Kim JS, Youn HJ, Kwon KB, Jung SH, Lee YR. Decursin prevents TPA-induced invasion through suppression of PKCα/p38/NF-κB-dependent MMP-9 expression in MCF-7 human breast carcinoma cells. Int J Oncol. 2014;44:1607–13.CrossRefPubMed
37.
Choi SR, Lee JH, Kim JY, Park KW, Jeong IY, Shim KH, Seo KI. Decursin from Angelicagigas Nakai induces apoptosis in RC-58T/h/SA# 4 primary human prostate cancer cells via a mitochondria-related caspase pathway. Food Chem Toxicol. 2011;49:2517–23.CrossRefPubMed
38.
Zhang J, Wang L, Zhang Y, Li L, Tang S, et al. Chemopreventive effect of Korean Angelica root extract on TRAMP carcinogenesis and integrative “omic” profiling of affected neuroendocrine carcinomas. Mol Carcinog. 2015;54:1567–83.CrossRefPubMed
39.
Lee HJ, Lee EO, Lee JH, Lee KS, Kim KH, et al. In vivo anti-cancer activity of Korean Angelica gigas and its major pyranocoumarin decursin. Am J Chin Med. 2009;37:127–42.CrossRefPubMed
40.
Nilsson S, Gustafsson J-Å. Biological role of estrogen and estrogen receptors. Crit Rev Biochem Mol Biol. 2002;37:1–28.CrossRefPubMed
41.
de Azevedo CRAS, Thuler LCS, de Mello MJG, de Oliveira Lima JT, da Fonte ALF, Fontão DFS, Carneiro VCG, Chang TMC, Ferreira CG. Phase II trial of neoadjuvant chemotherapy followed by chemoradiation in locally advanced cervical cancer. Gynecol Oncol. 2017;8258:31023–5.
42.
Hosseini A, Ghorbani A. Cancer therapy with phytochemicals.Evidence from clinical studies. Avicenna J Phytomed. 2015;5:84–97.PubMedPubMedCentral
43.
Maduro JH, Noordhuis MG, ten Hoor KA, Pras E, Arts HJ, Eijsink JJ, Hollema H, Mom CH, de Jong S, de Vries EG, de Bock GH, van der Zee AG. The prognostic value of TRAIL and its death receptors in cervical cancer. Int J Radiat Oncol Biol Phys. 2009;75:203–11.CrossRefPubMed
44.
Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007;7:585–98.CrossRefPubMed
45.
Ahn KS, Sethi G, Sung B, Goel A, Ralhan R, Aggarwal BB. Guggulsterone, a farnesoid X receptor antagonist, inhibits constitutive and inducible STAT3 activation through induction of a protein tyrosine phosphatase SHP-1. Cancer Res. 2008;68:4406–15.CrossRefPubMed
46.
Kim HJ, Kim SM, Park KR, Jang HJ, Na YS, Ahn KS, Ahn KS. Decursin chemosensitizes human multiple myeloma cells through inhibition of STAT3 signaling pathway. Cancer Lett. 2011;301:29–37.CrossRefPubMed
47.
Jang J, Jeong SJ, Kwon HY, Jung JH, Sohn EJ, Lee HJ, Kim JH, Kim SH, Kim JH, Kim SH. Decursin and doxorubicin are in synergy for the induction of apoptosis via stat3 and/or mtor pathways in human multiple myeloma cells. Evid Based Complement Alternat Med. 2013; 2013: 506324.
48.
Kim HH, Bang SS, Choi JS, Han H, Kim IH. Involvement of PKC and ROS in the cytotoxic mechanism of anti-leukemic decursin and its derivatives and their structure–activity relationship in human K562 erythroleukemia and U937 myeloleukemia cells. Cancer Lett. 2005;223:191–201.CrossRefPubMed
49.
Chaudhari K, Rizvi S, Syed BA. Rheumatoid arthritis: current and future trends. Nat Rev Drug Discov. 2016;15:305–6.CrossRefPubMed
50.
Giannelli G, Erriquez R, Iannone F, Marinosci F, Lapadula G, Antonaci S. MMP-2, MMP-9, TIMP-1 and TIMP-2 levels in patients with rheumatoid arthritis and psoriatic arthritis. Clin Exp Rheumatol. 2004;22:335–8.PubMed
51.
Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis 1. Endocr Rev. 2000;21:115–37.PubMed
52.
Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, Wagner EF. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell. 2002;3:889–901.CrossRefPubMed
53.
Takayanagi H. Osteoimmunology, shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunology. 2007;7:292–304.CrossRefPubMed
54.
Yagi M, Miyamoto T, Sawatani Y, Iwamoto K, Hosogane N, Fujita N, Oike Y. DC-STAMP is essential for cell–cell fusion in osteoclasts and foreign body giant cells. J Exp Med. 2005;202:345–51.CrossRefPubMedPubMedCentral
55.
Yagi M, Miyamoto T, Toyama Y, Suda T. Role of DC-STAMP in cellular fusion of osteoclasts and macrophage giant cells. J Bone Miner Metab. 2006;24:355–58.CrossRefPubMed
56.
Mensah KA, Ritchlin CT, Schwarz EM. RANKL induces heterogeneous DC-STAMPlo and DC-STAMPhi osteoclast precursors of which the DC-STAMPlo precursors are the master fusogens. J Cell Physiol. 2010;223:76–83.PubMedPubMedCentral
57.
Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer. 2002;2:91–100.CrossRefPubMed
58.
Kim KJ, Yeon JT, Choi SW, Moon SH, Ryu BJ, Yu R, Son YJ. Decursin inhibits osteoclastogenesis by downregulating NFATc1 and blocking fusion of pre-osteoclasts. Bone. 2015;81:208–16.CrossRefPubMed
59.
Wang X, Zheng T, Kang JH, Li H, Cho H, Jeon R, Ryu JH, Yim M. Decursin from Angelica gigas suppresses RANKL-induced osteoclast formation and bone loss. Eur J Pharmacol. 2016;774:34–42.CrossRefPubMed
60.
Gariano RF, Gardner TW. Retinal angiogenesis in development and disease. Nature. 2004;438:960–66.CrossRef
61.
Simó R, Hernández C. Intravitreous anti-VEGF for diabetic retinopathy. Hopes and fears for a new therapeutic strategy. Diabetologia. 2008;51:1574–80.CrossRefPubMed
62.
Qaum T, Xu Q, Joussen AM, Clemens MW, Qin W, Miyamoto K, Adamis AP. VEGF-initiated blood–retinal barrier breakdown in early diabetes. Inves ophthalmol vis sci. 2001;42:2408–13.
63.
Yang Y, Yang K, Li Y, Li X, Sun Q, Meng H, Zhang Y. Decursin inhibited proliferation and angiogenesis of endothelial cells to suppress diabetic retinopathy via VEGFR2. Mol Cell Endocrinol. 2013;378:46–52.CrossRefPubMed
64.
Ui-Jin B, Mi-Ra O, Tae-Sung J, Soo-Wan C, Byung-Hyun P. Decursin and decursinol angelate-rich Angelica gigas Nakai extract suppresses de novo lipogenesis and alleviates nonalcoholic fatty liver disease and dyslipidemia in mice fed a high fat diet. J Funct Foods. 2017;31:208–16.CrossRef
65.
66.
67.
68.
Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev. 2007;87:245–313.CrossRefPubMed
69.
Cui W, Matsuno K, Iwata K, Ibi M, Matsumoto M, Zhang J, Yabe-Nishimura C. NOX1/nicotinamide adenine dinucleotide phosphate, reduced form (NADPH) oxidase promotes proliferation of stellate cells and aggravates liver fibrosis induced by bile duct ligation. Hepatology. 2011;54:949–58.CrossRefPubMed
70.
Jiang JX, Chen X, Serizawa N, Szyndralewiez C, Page P, Schröder K, Török NJ. Liver fibrosis and hepatocyte apoptosis are attenuated by GKT137831: a novel NOX4/NOX1 inhibitor in vivo. Free Radic Biol Med. 2012;53:289–96.CrossRefPubMedPubMedCentral
71.
Feng XH, Derynck R. Specificity and versatility in TGF-β signaling through Smads. Annu Rev Cell Dev Biol. 2005;21:659–93.CrossRefPubMed
72.
Peiser M, Tralau T, Heidler J, et al. Allergic contact dermatitis: epidemiology, molecular mechanisms, in vitro methods and regulatory aspects. Cell Mol Life Sci. 2012;69:763–81.CrossRefPubMed
73.
Joo SS1, Park D, Shin S, Jeon JH, Kim TK, Choi YJ, Lee SH, Kim JS, Park SK, Hwang BY, Lee DI, Kim YB. Anti-allergic effects and mechanisms of action of the ethanolic extract of Angelica gigas in dinitrofluorobenzene-induced inflammation models. Environ Toxicol Pharmacol. 2010;30:127–33.CrossRefPubMed
74.
Shin S, Jeon JH, Park D, Jang JY, Joo SS, Hwang BY, Choe SY, Kim YB. Anti-inflammatory effects of an ethanol extract of Angelica gigas in a Carrageenan-air pouch inflammation model. Exp Anim. 2009;58:431–6.CrossRefPubMed
75.
Bonda DJ et al. Oxidative stress in Alzheimer disease: a possibility for prevention. Neuropharmacology. 2010;59:290–4.CrossRefPubMed
76.
Chauhan V, Chauhan A. Oxidative stress in Alzheimer’s disease. Pathophysiology. 2006;13:195–208.CrossRefPubMed
77.
Bhardwaj M, Deshmukh R, Kaundal M, Krishna Reddy BV. Pharmacological induction of hemeoxygenase-1 activity attenuates intracerebroventricular streptozotocin induced neurocognitive deficit and oxidative stress in rats. Eur J Pharmacol. 2016;772:43–50.CrossRefPubMed
78.
Kang SY, Kim YC. Decursinol and decursin protect primary cultured rat cortical cells from glutamate-induced neurotoxicity. J Pharm Pharmacol. 2007;59:863–70.CrossRefPubMed
79.
Li L, Du J, Zou L, Xia H, Wu T, Kim Y, Lee Y. The neuroprotective effects of decursin isolated from Angelica gigas nakai against amyloid β-protein-induced apoptosis in PC 12 cells via a mitochondria-related caspase pathway. Neurochem Res. 2015;40:1555–62.CrossRefPubMed
80.
Li L, Du JK, Zou LY, Wu T, Lee YW, Kim YH. Decursin isolated from Angelica gigas Nakai rescues PC12 cells from amyloid-protein-induced neurotoxicity through Nrf2-mediated upregulation of heme oxygenase-1: potential roles of MAPK. Evid Based Complement Alternat Med. 2013; 2013:467245.
81.
Kim KM, Lee YJ, Hong YG, Kang JS. Oral acute and subacute toxicity studies of decursin and decursinol angelate of Angelica gigas Nakai. Mol Cell Toxicol. 2009;5:153–9.
82.
Zhang J, Li L, Hale TW, Chee W, Xing C, Jiang C, Lü J. Single oral dose pharmacokinetics of decursin and decursinol angelate in healthy adult men and women. PloS One. 2015;10:e0114992.CrossRefPubMedPubMedCentral
Metadata
Title
Decursin and decursinol angelate: molecular mechanism and therapeutic potential in inflammatory diseases
Authors
Adeeb Shehzad
Sajida Parveen
Munibah Qureshi
Fazli Subhan
Young Sup Lee
Publication date
01-03-2018
Publisher
Springer International Publishing
Published in
Inflammation Research / Issue 3/2018
Print ISSN: 1023-3830
Electronic ISSN: 1420-908X
DOI
https://doi.org/10.1007/s00011-017-1114-7

Other articles of this Issue 3/2018

Inflammation Research 3/2018 Go to the issue

Review

Intracellular apoptotic pathways: a potential target for reducing joint damage in rheumatoid arthritis

Letter to the Editor

Altered mTORC1 signalling may contribute to macrophage dysregulation in hidradenitis suppurativa

Author Correction

Author Correction: Ouabain attenuates ovalbumin-induced airway inflammation

Original Research Paper

Piperlongumine inhibits the proliferation, migration and invasion of fibroblast-like synoviocytes from patients with rheumatoid arthritis

Original Research Paper

Mapping of the binding sites of human diamine oxidase (DAO) monoclonal antibodies

Original Research Paper

Angiotensin 1–7, but not the thrombin-cleaved osteopontin C-terminal fragment, attenuates osteopontin-mediated macrophage-induced endothelial-cell inflammation
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits